Literature DB >> 34202919

Mimicking Pathogens to Augment the Potency of Liposomal Cancer Vaccines.

Maarten K Nijen Twilhaar1, Lucas Czentner2, Cornelus F van Nostrum2, Gert Storm2,3,4, Joke M M den Haan1.   

Abstract

Liposomes have emerged as interesting vehicles in cancer vaccination strategies as their composition enables the inclusion of both hydrophilic and hydrophobic antigens and adjuvants. In addition, liposomes can be decorated with targeting moieties to further resemble pathogenic particles that allow for better engagement with the immune system. However, so far liposomal cancer vaccines have not yet reached their full potential in the clinic. In this review, we summarize recent preclinical studies on liposomal cancer vaccines. We describe the basic ingredients for liposomal cancer vaccines, tumor antigens, and adjuvants, and how their combined inclusion together with targeting moieties potentially derived from pathogens can enhance vaccine immunogenicity. We discuss newly identified antigen-presenting cells in humans and mice that pose as promising targets for cancer vaccines. The lessons learned from these preclinical studies can be applied to enhance the efficacy of liposomal cancer vaccination in the clinic.

Entities:  

Keywords:  antigen-presenting cells; cancer vaccines; liposomes; pathogen mimicry; targeting

Year:  2021        PMID: 34202919     DOI: 10.3390/pharmaceutics13070954

Source DB:  PubMed          Journal:  Pharmaceutics        ISSN: 1999-4923            Impact factor:   6.321


  143 in total

1.  Synthetic long peptide-based vaccine formulations for induction of cell mediated immunity: A comparative study of cationic liposomes and PLGA nanoparticles.

Authors:  Eleni Maria Varypataki; Ana Luisa Silva; Christophe Barnier-Quer; Nicolas Collin; Ferry Ossendorp; Wim Jiskoot
Journal:  J Control Release       Date:  2016-02-11       Impact factor: 9.776

2.  Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation.

Authors:  Juliette Mouriès; Gabriel Moron; Géraldine Schlecht; Nicolas Escriou; Gilles Dadaglio; Claude Leclerc
Journal:  Blood       Date:  2008-08-12       Impact factor: 22.113

Review 3.  Siglec-mediated regulation of immune cell function in disease.

Authors:  Matthew S Macauley; Paul R Crocker; James C Paulson
Journal:  Nat Rev Immunol       Date:  2014-09-19       Impact factor: 53.106

Review 4.  Dendritic Cells and Cancer Immunity.

Authors:  Alycia Gardner; Brian Ruffell
Journal:  Trends Immunol       Date:  2016-10-25       Impact factor: 16.687

5.  An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma.

Authors:  Ugur Sahin; Petra Oehm; Evelyna Derhovanessian; Robert A Jabulowsky; Mathias Vormehr; Maike Gold; Daniel Maurus; Doreen Schwarck-Kokarakis; Andreas N Kuhn; Tana Omokoko; Lena M Kranz; Mustafa Diken; Sebastian Kreiter; Heinrich Haas; Sebastian Attig; Richard Rae; Katarina Cuk; Alexandra Kemmer-Brück; Andrea Breitkreuz; Claudia Tolliver; Janina Caspar; Juliane Quinkhardt; Lisa Hebich; Malte Stein; Alexander Hohberger; Isabel Vogler; Inga Liebig; Stephanie Renken; Julian Sikorski; Melanie Leierer; Verena Müller; Heidrun Mitzel-Rink; Matthias Miederer; Christoph Huber; Stephan Grabbe; Jochen Utikal; Andreas Pinter; Roland Kaufmann; Jessica C Hassel; Carmen Loquai; Özlem Türeci
Journal:  Nature       Date:  2020-07-29       Impact factor: 49.962

6.  Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting.

Authors:  Jean-Sébastien Thomann; Béatrice Heurtault; Steffen Weidner; Mélanie Brayé; Julien Beyrath; Sylvie Fournel; Francis Schuber; Benoît Frisch
Journal:  Biomaterials       Date:  2011-04-07       Impact factor: 12.479

7.  Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity.

Authors:  Leticia Corrales; Laura Hix Glickman; Sarah M McWhirter; David B Kanne; Kelsey E Sivick; George E Katibah; Seng-Ryong Woo; Edward Lemmens; Tamara Banda; Justin J Leong; Ken Metchette; Thomas W Dubensky; Thomas F Gajewski
Journal:  Cell Rep       Date:  2015-05-07       Impact factor: 9.423

Review 8.  Therapeutic cancer vaccines.

Authors:  Cornelis J M Melief; Thorbald van Hall; Ramon Arens; Ferry Ossendorp; Sjoerd H van der Burg
Journal:  J Clin Invest       Date:  2015-07-27       Impact factor: 14.808

9.  Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.

Authors:  Matthew M Gubin; Xiuli Zhang; Heiko Schuster; Etienne Caron; Jeffrey P Ward; Takuro Noguchi; Yulia Ivanova; Jasreet Hundal; Cora D Arthur; Willem-Jan Krebber; Gwenn E Mulder; Mireille Toebes; Matthew D Vesely; Samuel S K Lam; Alan J Korman; James P Allison; Gordon J Freeman; Arlene H Sharpe; Erika L Pearce; Ton N Schumacher; Ruedi Aebersold; Hans-Georg Rammensee; Cornelis J M Melief; Elaine R Mardis; William E Gillanders; Maxim N Artyomov; Robert D Schreiber
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

10.  Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity.

Authors:  Kai Hildner; Brian T Edelson; Whitney E Purtha; Mark Diamond; Hirokazu Matsushita; Masako Kohyama; Boris Calderon; Barbara U Schraml; Emil R Unanue; Michael S Diamond; Robert D Schreiber; Theresa L Murphy; Kenneth M Murphy
Journal:  Science       Date:  2008-11-14       Impact factor: 47.728

View more
  1 in total

1.  Incorporation of Toll-Like Receptor Ligands and Inflammasome Stimuli in GM3 Liposomes to Induce Dendritic Cell Maturation and T Cell Responses.

Authors:  Maarten K Nijen Twilhaar; Lucas Czentner; Rianne G Bouma; Katarzyna Olesek; Joanna Grabowska; Aru Zeling Wang; Alsya J Affandi; Saskia C Belt; Hakan Kalay; Cornelus F van Nostrum; Yvette van Kooyk; Gert Storm; Joke M M den Haan
Journal:  Front Immunol       Date:  2022-02-18       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.